Advertisement

Der Ophthalmologe

, Volume 116, Issue 2, pp 144–151 | Cite as

Orale Antikoagulation

Aktuelle Übersicht und perioperatives Management in der Ophthalmochirurgie
  • C. SuckerEmail author
  • A. Hager
  • J. Koscielny
  • N. Feltgen
Übersichten
  • 162 Downloads

Zusammenfassung

Eine antithrombotische Medikation mit oralen Antikoagulanzien und Plättchenfunktionshemmern erhöht das perioperative Blutungsrisiko. Im Gegensatz zu anderen chirurgischen Fachgebieten ist das optimale perioperative Management dieser Medikamente bei opthalmochirurgischen Eingriffen derzeit nicht verbindlich festgelegt und standardisiert. In dieser Arbeit geben wir eine Übersicht über aktuell verfügbare orale Antikoagulanzien und stellen das mögliche Vorgehen in Bezug auf die Antikoagulation im Rahmen verschiedener augenärztlicher Eingriffe dar.

Schlüsselwörter

Ophthalmochirurgie Perioperatives Blutungsrisiko Orale Antikoagulanzien Vitamin-K-Antagonisten Nicht-Vitamin-K-abhängige orale Antikoagulanzien Management 

Oral anticoagulation

Current overview and perioperative management in ophthalmic surgery

Abstract

Antithrombotic treatment with oral anticoagulants and antiplatelet agents can increase the risk for perioperative bleeding. In contrast to other surgical fields, the optimal perioperative management in ophthalmic surgery has not yet been exactly defined and, thus, is not standardized. In this contribution, we provide an overview of currently available oral anticoagulants and discuss potential strategies for the management of these agents in different ophthalmic surgical procedures.

Keywords

Ophthalmic surgery Perioperative bleeding risk Oral anticoagulants Vitamin K antagonists Non-vitamin K antagonist oral anticoagulants Management 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

C. Sucker, A. Hager, J. Koscielny und N. Feltgen geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Ageno W, Eikelboom J, Lip GY (2016) Dabigatran in clinical practice: contemporary overview of the evidence. Int J Cardiol 220:417–428CrossRefGoogle Scholar
  2. 2.
    Alhassan MB, Kyari F, Ejere HO (2015) Peribulbar versus retrobulbar anaesthesia for cataract surgery. Cochrane Database Syst Rev.  https://doi.org/10.1002/14651858.CD004083.pub3 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Baglin T (2013) Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban. Br J Haematol 163:160–167PubMedGoogle Scholar
  4. 4.
    Bauersachs R (2016) Non-vitamin K antagonist oral anticoagulants for the prevention of recurrent venous thromboembolism. Thromb Res 144:12–20CrossRefGoogle Scholar
  5. 5.
    Benzimra JD, Johnston RL, Jaycock P, Galloway PH, Lambert G, Chung AKK et al (2009) The Cataract National Dataset electronic multicentre audit of 55,567 operations: antiplatelet and anticoagulant medications. Eye (Lond) 23:10–16CrossRefGoogle Scholar
  6. 6.
    Blair HA, Keating GM (2017) Dabigatran etexilate: a review in nonvalvular atrial fibrillation. Drugs 77:331–344CrossRefGoogle Scholar
  7. 7.
    Brown JS, Mahmoud TH (2011) Anticoagulation and clinically significant postoperative vitreous hemorrhage in diabetic vitrectomy. Retina 31:1983–1987CrossRefGoogle Scholar
  8. 8.
    Dayani PN, Grand MG (2006) Maintenance of warfarin anticoagulation for patients undergoing vitreoretinal surgery. Arch Ophthalmol 124:1558–1565CrossRefGoogle Scholar
  9. 9.
    Dayani PN, Siddigi OK, Holekamp NM (2007) Safety of intravitreal injections in patients receiving warfarin anticoagulation. Am J Ophthalmol 144:451–453CrossRefGoogle Scholar
  10. 10.
    Feltgen N, Pielen A, Hattenbach LO, Geisen U, Heinz J (2010) Perioperative conversion of oral anticoagulants to heparin (bridging) in ophthalmic medicine. Ophthalmologe 107:636–640CrossRefGoogle Scholar
  11. 11.
    Feltgen N, Hoerauf H, Noske W, Hager A, Koscielny J (2016) Platelet aggregation inhibitors and anticoagulants during ophthalmic interventions. Ophthalmologe 113:1010–1022CrossRefGoogle Scholar
  12. 12.
    Gibson CM, Finks SW (2017) Edoxaban: How does the newest agent fit into the DOAC landscape? Am J Med 130:900–906CrossRefGoogle Scholar
  13. 13.
    Hurst KV, O’Callaghan JM, Handa A (2017) Quick reference guide to apixaban. Vasc Health Risk Manag 13:263–267CrossRefGoogle Scholar
  14. 14.
    Kallio H, Paloheimo M, Maunuksela EL (2000) Haemorrhage and risk factors associated with retrobulbar/peribulbar block: a prospective study in 1383 patients. Br J Anaesth 85:708–711CrossRefGoogle Scholar
  15. 15.
    Katz J, Feldman MA, Bass EB, Lubomski LH, Tielsch JM, Patty BG, Fleisher LA, Schein OD, Study of Medical Testing for Cataract Surgery Team (2003) Risks and benefits of anticoagulant and antiplatelet medication use before cataract surgery. Ophthalmology 110:1784–1788CrossRefGoogle Scholar
  16. 16.
    Kreutz R (2014) Pharmacokinetics and pharmacodynamics of rivaroxaban- an oral, direct factor Xa inhibitor. Curr Clin Pharmacol 9:75–83CrossRefGoogle Scholar
  17. 17.
    Mason JO, Frederick PA, Neimkin MG, White MF, Feist RM, Thomley ML, Albert MA (2010) Incidence of hemorrhagic complications after intravitreal bevacizumab (avastin) or ranibizumab (lucentis) injections on systemically anticoagulated patients. Retina 30:1386–1389.  https://doi.org/10.1097/IAE.0b013e3181e09739 CrossRefPubMedGoogle Scholar
  18. 18.
    Plitt A, Ruff CT, Giugliano RP (2016) Non-vitamin K antagonist oral anticoagulants in atrial fibrillation. Hematol Oncol Clin North Am 30:1019–1034CrossRefGoogle Scholar
  19. 19.
    Poulakos M, Walker JN, Baig U, David T (2017) Edoxaban: a direct oral anticoagulant. Am J Health Syst Pharm 74:117–129CrossRefGoogle Scholar
  20. 20.
    Pozzi M, Mitchell J, Henaine AM, Hanna N, Safi O, Henaine R (2016) International normalized ratio self-testing and self-management: improving patient outcomes. Vasc Health Risk Manag 12:387–392 (eCollection 2016)CrossRefGoogle Scholar
  21. 21.
    Ryan A, Saad T, Kirwan C, Keegan DJ, Acheson RW (2013) Maintenance of perioperative antiplatelet and anticoagulant therapy for vitreoretinal surgery. Clin Exp Ophthalmol 41:387–395CrossRefGoogle Scholar
  22. 22.
    Sankaranarayanan R, Fox DJ (2016) Are some anticoagulants more equal than others? – Evaluating the role of novel oral anticoagulants in AF ablation. Curr Cardiol Rev 12:330–335CrossRefGoogle Scholar
  23. 23.
    Sucker C, Litmathe J (2017) Oral anticoagulation using coumarins – an update. Wien Med Wochenschr.  https://doi.org/10.1007/s10354-017-0577-z CrossRefPubMedGoogle Scholar
  24. 24.
    Werth S, Breslin T, NiAinle F, Beyer-Westendorf J (2015) Bleeding risk, management and outcome in patients receiving Non-VKA Oral Anticoagulants (NOAcs). Am J Cardiovasc Drugs 15:235–242CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Gerinnungszentrum Berlin Dr. SuckerBerlinDeutschland
  2. 2.GerinnungsambulanzCharitéBerlinDeutschland
  3. 3.Augenarztpraxis am ElsterplatzBerlinDeutschland
  4. 4.AugenklinikUniversitätsmedizin GöttingenGöttingenDeutschland

Personalised recommendations